BetterLife CEO Discusses Merger, Planned Interferon Treatment Trials and Potential Subsequent FDA Emergency Use Authorization

New York City, July 23, 2020 (GLOBE NEWSWIRE) — The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR), an emerging biotechnology company currently preparing its own interferon-based coronavirus treatment clinical trials, recently joined online portal Proactive for a Q&A which included the upcoming merger with Altum Pharmaceuticals, interferon inhalation treatment for COVID-19, what the upcoming trials means for BetterLife, and what advantages AP-003’s interferon alpha2b (IFNa2b) may have over interferon beta treatments.
In the online interview, Dr. Doroudian discusses:Why BetterLife plans to kick off its 150 patient Phase 2 clinical trials of the company’s COVID-19 therapeutic AP-003, which uses a nebulizer to deliver the drug directly to the lungs as a fine mist.
 
The expectation that the AP-003 Phase 2 trials will be completed in the next three to six months, and subsequent US FDA Emergency Use Authorization
 
BetterLife’s agreement with Altum to work towards finalizing a “merger of equals.”
 
Recent studies validating interferon as effective against COVID-19 and other respiratory viruses. 
 
The company’s development of a topical interferon for treatment of human papillomavirus (HPV). The full interview can be found here.To learn more about AP-003 please visit www.BlifeTherapeutics.comDisclosure: BetterLife Pharma is a client of BDA International.About BDA International, Inc.:BDA International is an independent global firm offering a wide range of IR and PR related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including BETRF. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and BETRF may do so via the contact information at the bottom of this release.DisclaimerThe information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. BetterLife Pharma is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.Investor Relations Contact:
Dost Mushtaq                                                                      
BDA International    
www.bda-ir.com
dost@bda-ir.com   


CBJ Newsmakers

Recommended
WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in CoronavirusWestport Fuel Systems Secures US$10 Million Credit Facility from Export Development Canada